Abstract
We previously demonstrated a circadian rhythm in response to docetaxel chemotherapy in C3H/HeN mice bearing MA13/C mammary adenocarcinoma. We investigated the relation between this rhythm and the expression of BCL-2 in bone marrow and in tumor tissues. A circadian rhythm characterized BCL-2 expression in the bone marrow, which was hardly modified in tumor-bearing animals. BCL-2 acrophase coincided with the time of highest docetaxel tolerability and efficacy in this model. This suggests that BCL-2 protects the bone marrow from the drug toxicity, especially during the light phase.
MeSH terms
-
Adenocarcinoma / genetics
-
Adenocarcinoma / physiopathology*
-
Adenocarcinoma / secondary
-
Animals
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Antineoplastic Agents, Phytogenic / toxicity
-
Bone Marrow / metabolism
-
Bone Marrow Diseases / chemically induced
-
Bone Marrow Diseases / prevention & control
-
Chronotherapy
-
Circadian Rhythm / genetics*
-
Docetaxel
-
Gene Expression Regulation, Neoplastic / physiology*
-
Genes, bcl-2*
-
Male
-
Mammary Neoplasms, Experimental / drug therapy
-
Mammary Neoplasms, Experimental / genetics
-
Mammary Neoplasms, Experimental / physiopathology*
-
Mice
-
Mice, Inbred C3H
-
Neoplasm Proteins / biosynthesis*
-
Neoplasm Proteins / genetics
-
Neoplasm Transplantation
-
Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
-
Taxoids / administration & dosage
-
Taxoids / therapeutic use
-
Taxoids / toxicity
Substances
-
Antineoplastic Agents, Phytogenic
-
Neoplasm Proteins
-
Proto-Oncogene Proteins c-bcl-2
-
Taxoids
-
Docetaxel